Philippa Quy

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

Joyce F. Liu, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2014 · 584 citations · Full text

Medicine, Gynecology, Oncology +16

Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC).

Ursula A. Matulonis, Gerburg M. Wulf, Michael J. Birrer et al. · Journal of Clinical Oncology · 2014 · 36 citations

Medicine, Oncology, Pharmacology +15

A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.

Joyce F. Liu, William T. Barry, Michael J. Birrer et al. · Journal of Clinical Oncology · 2014 · 22 citations

Medicine, Oncology, Pharmacology +14

A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.

Joyce F. Liu, William T. Barry, Michael J. Birrer et al. · Journal of Clinical Oncology · 2014 · 13 citations

Medicine, Oncology, Pharmacology +14